Background Direct oral anticoagulants (DOACs) are the treatment of choice for most patients
with atrial fibrillation and/or noncancer-associated venous thromboembolic disease …

Background In case of bleeding patients and in acute care, the assessment of residual direct
oral anticoagulant (DOAC) activity is essential for evaluating the potential impact on …

Apixaban does not require monitoring nor frequent dose adjustment. However, searching for
the optimal dose for the individual patient may be useful in some situations. Moreover, there …

Direct oral anticoagulants (DOACs) account for most oral anticoagulant use. DOAC-
associated bleeding events are commonly encountered in clinical practice and are …

The systems analysis of thrombosis seeks to quantitatively predict blood function in a given
vascular wall and hemodynamic context. Relevant to both venous and arterial thrombosis, a …

Abstract Introduction Rotational Thromboelastometry (ROTEM) is a point of care method
used to monitor coagulation during surgery and to guide transfusion strategies in patients …

Background Andexanet alfa (andexanet) is a modified human factor Xa (FXa) approved for
anticoagulation reversal in patients with life‐threatening bleeding treated with rivaroxaban …

BACKGROUND Rapid detection of the anticoagulant effect of oral factor Xa (FXa) inhibitors
may be essential in several emergency clinical situations. Specific assays quantifying the …

The article discusses research which investigated how direct oral anticoagulants (DOAC)
plasma level thresholds may impact thrombin generation assay (TGA) results being used for …

The currently available oral anti-Xa agents are claimed to produce their anticoagulant and
antithrombotic effects solely by the inhibition of factor Xa. This study profiled various anti-Xa …